Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus


Project Status:
Open for Stakeholder Feedback
Project Line:
Reimbursement Review
Project Sub Line:
Streamlined Drug Class Review
Project Number:

The class of sodium-glucose cotransporter-2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes mellitus. Evidence informing the place in therapy of SGLT2 inhibitors has matured since CADTH last assessed this drug class. Public drug programs have requested a review to assess the optimal use of SGLT2 inhibitors after a trial of metformin.

This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects in Progress.

Call for feedback
Call for feedback:
Feedback Due By
Feedback Due By:
Consultation document
Consultation document: Proposed Project Scope
Product Line
Product Line: Reimbursement Review
Project Number
Project Number: TS0002-000
Key Milestones2
Posting of Draft Scope for stakeholder feedbackSeptember 14
End of feedback periodSeptember 28